Global Immune Checkpoint Inhibitors Market to Surpass US$ 40.8 Billion by 2026 - Coherent Market Insights


SEATTLE, March 26, 2019 (GLOBE NEWSWIRE) -- According to Coherent Market Insights, the global immune checkpoint inhibitors market was valued at US$ 10,543.8 million in 2017, and is projected to exhibit a CAGR of 11.8% over the forecast period (2018–2026).

Key Trends and Analysis of the Immune Checkpoint Inhibitors Market:

Factors such as increasing number of approvals and launches of novel therapies are expected to support the global immune checkpoint inhibitors market growth. For instance, in the recent past, therapies such as Keytruda, Opdivo, Imfinzi, and others have received approvals for multiple indications. Moreover, manufacturers are indulged in research and development of combination therapies of immuno checkpoint inhibitors with other checkpoint inhibitor, and other therapies such as chemotherapy drugs. For instance, combination of nivolumab and ipilimumab for the treatment of intermediate- or poor-risk patients with previously untreated advanced renal cell carcinoma was approved in the U.S. in 2018, and in January 2019 in Europe.

Request for a Sample Copy of this Report @ https://www.coherentmarketinsights.com/insight/request-sample/2560

Cancer is a class of chronic disease that is characterized by out-of-controlled growth of cells. The National Cancer Institute, 2013 states that there are over 100 different types of cancers that can be described from the type of cells they are formed from. According to the American Cancer Society, 2017, cancer is the second most common cause of death in the U.S., which accounts for nearly 1 out of every 4 deaths. According to the World Health Organization, 2012, cancer is the second leading cause of morbidity and mortality worldwide, with around 14 million new cases registered in 2012. Furthermore, WHO also stated that the number of new cases is expected to rise around 70% by 2030. Also, in 2015, cancer was responsible for 8.8 million deaths globally, accounting for around 1 in 6 deaths mainly in low- and middle-income countries. Thus, in order to cater increasing demand for cancer drugs, manufacturers are focusing on developing novel products for treatment of cancer. This is expected to aid in growth of the market.

Leading players are actively investing in research and development in oncology treatment through various collaborations and individual research studies, owing to benefits associated with immune-oncology therapies. Advent of innovative immune-oncology therapies such as immune checkpoint inhibitors, have supported growth of the market. For instance, in 2015, Sanofi and Regeneron Pharmaceuticals, Inc. entered into strategic collaboration, to develop and commercialize new antibody cancer treatment (SAR439684) in the oncology market. The companies are developing an antibody-based cancer therapy- REGN2810 (SAR439684) for the treatment of cutaneous squamous cell carcinoma, which is currently in clinical phase 2.

To know the latest trends and insights prevalent in this market, click the link below:

https://www.coherentmarketinsights.com/market-insight/immune-checkpoint-inhibitors-market-2560

Key Market Takeaways:

  • The global immune checkpoint inhibitors market is expected to exhibit a CAGR of 11.8% over the forecast period. This is attributed to presence of number of leading manufacturers who are focusing on bringing out innovative therapies through extensive research and development such as Bristol Myers Squibb, Novartis, and Pfizer, Inc.
  • Biopharmaceutical companies are developing a robust pipeline of immune checkpoint inhibitors combination therapies due to increasing demand for the same. The U.S. Food & Drug Administration has approved a number of immune checkpoint inhibitors including Yervoy (anti-CTLA-4), Opdivo and Keytruda (anti-PD1) and Tecentriq (anti-PD-L1).
  • Immuno-checkpoint inhibitor combination therapies are expected to change the market scenario over the forecast period, owing to positive results in the clinical trials
  • Research partnerships and collaborations to develop new drugs by various market players is supporting growth of the market, as competitors are striving to gain competitive edge in the market.
  • Major players operating in the global immune checkpoint inhibitors market include Bristol-Myers Squibb Company, Merck & Co., Inc., F. Hoffmann-La Roche AG, AstraZeneca Plc., Novartis International AG, ImmunOs Therapeutics AG, Immutep Ltd., NewLink Genetics Corporation, Ono Pharmaceutical Co., Ltd., and Pfizer, Inc.

            

Contact Data